SCHEMBL4665833

SCHEMBL4665833

CN1CCC(COc2ccc(-c3cc(Nc4ccc(N(OC=O)S(=O)(=O)c5c(F)cccc5F)cc4)ncn3)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.41
AURKA O14965 1/20 0.41
CDK1 P06493 1/20 0.41
PDGFRB P09619 1/20 0.41
PDGFRA P16234 1/20 0.41
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
ABL1 P00519 7/20 0.41
BCR P11274 7/20 0.41
EGFR P00533 2/20 0.40
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
GLA P06280 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4667408 0.93 ABL1 (0.40) ABL1BCRMEN1USP2ALDH1A1
SCHEMBL4666106 0.93 ABL1 (0.42) KDRAURKACDK1PDGFRBPDGFRA
SCHEMBL4667543 0.92 EGFR (0.39) KDRAURKACDK1PDGFRBPDGFRA
SCHEMBL4665711 0.90 EGFR (0.38) KDRAURKACDK1PDGFRBPDGFRA
SCHEMBL4667471 0.90 EGFR (0.44) KDRPDGFRBPDGFRAFLT1FLT4
SCHEMBL4665770 0.90 MEN1 (0.42) KDRAURKACDK1PDGFRBPDGFRA
SCHEMBL4666074 0.89 MEN1 (0.45) KDRAURKACDK1PDGFRBPDGFRA
SCHEMBL4664352 0.89 KDR (0.38) KDRAURKACDK1PDGFRBPDGFRA
SCHEMBL4664327 0.88 ABL1 (0.41) ABL1BCRMEN1USP2ALDH1A1
SCHEMBL4665665 0.87 ABL1 (0.41) PDGFRBABL1BCRMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 KDR 431/4885AURKA 373/4885CDK1 68/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.